ReviewGastroenterology2012
Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
Review in Gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01831037 (The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Pooled it
- Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study.Hepatology (Baltimore, Md.) · 2013Trial
- Hepatitis C virus infection in blood donors in Santa Catarina, Brazil, 2010-2020.Transfusion medicine (Oxford, England) · 2025Article
- Unraveling the therapeutic landscape of approved non-peptide macrocycles.Acta pharmaceutica Sinica. B · 2025Review
- Screening for Hepatitis C Virus: How Universal Is Universal?Clinical therapeutics · 2020Review
- Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals.Pharmacogenomics and personalized medicine · 2017Review
- Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement.Hepatic medicine : evidence and research · 2017Article
- Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes.Current gastroenterology reports · 2016Review
- Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy.Hepatitis research and treatment · 2016Article
- Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.Journal of hepatology · 2015Observational
- Observational
- Analysis of the Enzymatic Activity of an NS3 Helicase Genotype 3a Variant Sequence Obtained from a Relapse Patient.PloS one · 2015Article
- New therapies for hepatitis C: Latin American perspectives.Clinical liver disease · 2015Review
- Review
- Management of viral hepatitis in liver transplant recipients.Clinical and molecular hepatology · 2014Review
- New treatments for chronic hepatitis C: an overview for paediatricians.World journal of gastroenterology · 2014Review
- Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.European journal of gastroenterology & hepatology · 2014Observational
- Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.World journal of gastroenterology · 2014Review
- Membranoproliferative glomerulonephritis, type II cryoglobulinemia and triple therapy for hepatitis C: a case series and review of the literature.Digestive diseases and sciences · 2014Review
- Chronic hepatitis C genotype 1 virus: who should wait for treatment?World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Recently developed drugs and innovative strategies for the treatment of chronic infection with genotype 1 hepatitis C virus (HCV) have become the standard of care. The protease inhibitors telaprevir (Incivek) and boceprevir (Victrelis) are the first direct-acting antiviral (DAA) agents approved, and many more are being developed. These drugs substantially increased rates of sustained virologic response in treatment-naïve and -experienced patients, in conjunction with peginterferon and ribavirin (triple therapy), in phase 3 trials. The efficacy of triple therapy depends on appropriate selection of patients, although the population of patients that receive triple therapy could be expanded as the risk/benefit ratio improves. Attention to details that reflect the standard of care, such as appropriate dosing, anticipation of adverse effects, and strict adherence to stopping rules, will insure the success of these drugs and lead the way for new combination therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.